New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
07:46 EDTPCYCPharmacyclics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Pharmacyclics to Outperform citing increased expectations for Imbruvica in Chronic Lymphocytic Leukemia. After surveying 57 hematologists/oncologists, Leerink has an improved outlook for the drug. The firm raised its price target for shares to $142 from $102.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
11:46 EDTPCYCPharmacyclics confirms FDA approval of IMBRUVICA
Subscribe for More Information
10:50 EDTPCYCFDA expands use of Imbruvica to rare form of cancer
The FDA expanded the approved use of Imbruvica for previously treated patients with Waldenström’s macroglobulinemia, a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. The product's new use is being approved more than two months ahead of its prescription drug user fee goal date of April 17, the date the FDA was scheduled to complete review of the drug application. Imbruvica is co-marketed by Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Janssen Biotech unit.
January 22, 2015
08:29 EDTPCYCPharmacyclics price target raised to $253 from $204 at JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use